Clinical Trials
3 trialsNCT03721978 2024-10-17
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Inovio Pharmaceuticals
Phase 3 Completed
NCT03185013 2023-07-27
REVEAL 1
Inovio Pharmaceuticals
Phase 3 Completed
NCT03499795 2023-07-14
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Inovio Pharmaceuticals
Phase 2 Completed